Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study

By sjmartinez • May 19, 2025

Krebs MG, Cho BC, Hiret S, Han JY, Lee KH, Llácer Pérez C, De Braud F, Haura EB, Sanborn RE, Yang JC, Shu CA, Goto K, Nishio M, Zhao J, Wang Z, Tomasini P, Felip E, Goldman JW, Ou SI, Boyer M, Gao G, Qu S, Curtin JC, Lyu X, Schnepp RW, Kim P, Thayu M, Knoblauch RE, Lorenzini P, Baig M, Spira AI, Leighl NB. Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study. J Thorac Oncol. 2025 May 16:S1556-0864(25)00720-8. doi: 10.1016/j.jtho.2025.05.012. Epub ahead of print. PMID: 40383434.

Tags: advanced non-small cell lung cancer, amivantamab, CHRYSALIS, Hematology/Oncology, MET exon 14 skipping mutation, prior MET therapies, Publications

Complex Tricuspid and Pulmonic Carcinoid Heart Disease With Timely Surgical Repair

Hollowed J, Woo H, Hamburg S, Ardehali A. Complex Tricuspid and Pulmonic Carcinoid Heart Disease With Timely Surgical Repair. Tex Heart Inst J. 2025 Jul[...]

Incomplete Cancer Surgery Correlates With Loss of Immune Surveillance and Hyper-Progression of Disease

Fine SA, Lim SY, Siena NM, de Jesus AB, Goh T, Markus L, Russell TA, Kendal JK, Lofftus SY, Shehata MS, Dao HB, Lee A,[...]

Elevated Adrenocorticotropic Hormone After Adrenalectomy or Adrenal Ablation and Immune Checkpoint Inhibitors: Adrenal Insufficiency Is Not Always the Culprit

Shabsovich D, Kathuria-Prakash N, Zhang J, Cabral M, Lopez L, Sumal A, Drakaki A. Elevated Adrenocorticotropic Hormone After Adrenalectomy or Adrenal Ablation and Immune Checkpoint[...]